Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Clin Exp Allergy. 2013 Mar;43(3):292–303. doi: 10.1111/j.1365-2222.2012.04065.x

Fig. 2.

Fig. 2

Expression of epitope for mAb KIM-127 in intermediate- and high-activity β2-integrins versus forward scatter of eosinophils before and after anti-IL-5 administration. Representative dot plots of KIM-127 epitope expression versus forward scatter on blood eosinophils pre-segmental antigen challenge (A) and on blood (B) and BAL (C) eosinophils 48 h post-segmental antigen challenge before (green) and after (purple) anti-IL-5. Data acquisition time was 1 min, and thus the number of dots varies according to the numbers of eosinophils. KIM-127 epitope expression on blood eosinophils pre-segmental antigen challenge was significantly lower after anti-IL-5 than before anti-IL-5 when these data were combined with data from the other subjects (Table 2). Forward scatter of blood eosinophils 48 h post-segmental antigen challenge was significantly lower after anti-IL-5 than before anti-IL-5 (Table 2).